1 Title page

Title: Health and economic impact of the human papillomavirus (HPV) vaccine in Mozambique

Authors: Paula Christen*[1,2] (PhD), Agostinho Viana Lima[3] (MSc), Muanacha Mintade[3] (MSc), Neusa Torres[3] (PhD), Timothy B. Hallett[1] (PhD), Lesong Conteh[4,5] (PhD), Allison Portnoy[6] (ScD)

---

[1]Medical Research Council Centre for Global Infectious Disease Analysis, Faculty of Medicine, Imperial College London, London, UK

[2]Center for Epidemiological Modelling and Analysis (CEMA), University of Nairobi, Nairobi, Kenya

[3]Manhiça Health Research Centre (CISM), Manhiça, Mozambique

[4]Department of Health Policy, London School of Economics, London, UK

[5]LSE Health, London School of Economics, London, UK

[6]Department of Global Health, Boston University School of Public Health, Boston, MA, USA

*Corresponding author: UNITID building, Faculty of Health Sciences, University of Nairobi, Kenyatta National Hospital Grounds, off Ngong Road, Nairobi, Kenya, paula.christen16@imperial.ac.uk, ORCID: 0000-0003-4671-3973

Author contributor statement:

- Conception or design of the work: PC, AP

- Data collection: PC, AL, MM

- Data analysis and interpretation: PC, AL, MM

- Drafting the article: PC

- Critical revision of the article: PC, MM, TH, LC

- Final approval of the version to be submitted: PC, AP, AL, MM, NT, TH, LC

Reflexivity statement: In conducting this modeling study, we acknowledge that our backgrounds, experiences, and perspectives have inevitably influenced the research process. The authors include five females and two males and span multiple levels of seniority. The team comprises two senior researchers specializing in health economics with

a focus on vaccine impact, four social scientists with extensive experience in qualitative research, and three mathematical modellers of infectious diseases. Three of the authors are based in Mozambique at an institution actively engaged in policy dialogues on infectious disease interventions, including the HPV vaccination program. As mathematical modelers, health economists, and health policy and systems researchers, our disciplinary orientations and prior knowledge shaped how we interpreted data and conducted the overall analysis. Recognizing these influences, we sought to mitigate potential biases through collaborative engagement with local experts, iterative feedback, and reflexive consideration of how our perspectives informed the study's direction and conclusions.

Keywords: Mozambique; Extended cost-effectiveness analysis; cervical cancer; equity; human papillomavirus; vaccination.

Word count: 4135

Ethical Approval: Ethical approval for this type of study is not required by our institute.

Funding: PC and TH acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. The study was part of a doctoral study programme (for PC) that was supported by the London Interdisciplinary Social Science Doctoral Training Programme (LISS DTP), funded by the Economic and Social Research Council (ESRC).

Acknowledgements: An earlier version of this paper was presented at the International Papillomavirus Conference and a seminar at Imperial College London and the University of Nairobi, where we received valuable comments from participants. We also appreciate the input of study participants of preceding qualitative research, who shaped the research questions posed in this study and gave access to vaccine coverage data.

Conflicts of interest: The authors declare that they have no conflict of interest.

2   Abstract

Mozambique is among the countries with the highest cervical cancer (CC) incidence rates in the world. Yet, in sub-Saharan Africa, only 5% of CC patients receive appropriate treatment. In 2021, Mozambique integrated the prophylactic human papillomavirus (HPV) vaccine into its national immunization program as a primary prevention strategy. As part of a qualitative research effort on participatory modeling, this study aimed to quantify the magnitude and distribution of expected health and economic outcomes of the current HPV vaccination program, hypothetical scale-up scenarios, and global targets.

We applied and extended a closed cohort model to quantify the vaccine program's direct potential population health benefits (in averted CC cases and deaths), financial savings to patients (in direct medical treatment costs saved and in financial risk protection provided), health provider benefits measures in saved labour (full-time equivalents, FTEs) and distribution of benefits under empirically informed and potential vaccination coverage scenarios.

With a coverage of 18.9% in 2021, the vaccination program is estimated to avert up to 9.7% of expected CC cases and deaths (from 4.0% in the highest socioeconomic quintile (HQ) to 11.6% in the lowest socioeconomic quintile (LQ)). Across the lifetime of a single vaccination cohort, an average of US$106,532 (min: US$48,382, max: US$157,811) in direct medical CC treatment expenditure for patients and the time equivalent to 59 full-time healthcare workers is saved per year. Over 30 years, 50% vaccination coverage could prevent 23.9% of predicted cases and fatalities (LQ: 25.2% to HQ: 14.8%). With a gradient in vaccine coverage favoring higher socioeconomic quintiles in urban areas, the benefits in the LQ rural population are estimated to be six times greater than in the LQ urban population.

These findings can contribute to fair and efficient planning decisions from various stakeholder perspectives in policy dialogues around the HPV vaccination programme in Mozambique, and at a global level.

3   Key messages

- This study evaluates the health and economic effects of Mozambique's HPV vaccination program using a cohort-based modeling approach, estimating reductions in cervical cancer cases, financial burden, and healthcare system demands.

- At 50% vaccine coverage, the program could avert 26% of expected cervical cancer cases and deaths, with the highest impact observed among lower-income populations who face greater disease burden and limited access to care.

- The financial benefits extend beyond individual health gains, as the program could reduce catastrophic health expenditures, alleviate pressure on the healthcare workforce, and contribute to more equitable health outcomes.

- These insights support strategic decision-making on HPV vaccination expansion, highlighting the need for targeted efforts to maximize both effectiveness and equity in Mozambique's cancer prevention initiatives.

4   Introduction

Cervical cancer (CC), primarily caused by persistent infection with high-risk human papillomavirus (HPV) types, remains a significant health burden globally, disproportionately affecting women in low- and middle-income countries (LMICs) (De Martel *et al.*, 2017). In Mozambique, CC is the leading cause of cancer death (International agency for research on cancer - The Global Cancer Observatory, 2022). In 2020, Mozambique had one of the world's highest estimated age-standardized CC incidence rates (50.2 per 100,000), 3.7 times higher than the global average (13.3 per 100,000) and 2.4 times higher than the southern African regional estimate (20.6 per 100,000) (Sung *et al.*, 2021). Like many LMICs, Mozambique faces significant challenges in CC prevention and control due to limited

healthcare resources (Lorenzoni *et al.*, 2018; Tulsidás *et al.*, 2023), low screening coverage (Brandão *et al.*, 2019), and high treatment costs (Omotoso *et al.*, 2023).

The introduction of the HPV vaccine in November 2021 presents a promising strategy to reduce the health and economic burden of CC in Mozambique. However, the success of the vaccination programme depends on vaccine coverage, health system capacity, and socioeconomic factors. Disparities in disease burden and vaccine uptake across socioeconomic groups can significantly shape its impact on health equity (Sacre *et al.*, 2023; Abbas *et al.*, 2024). Despite efforts to ensure equitable healthcare access, marginalized groups remain underserved (Ali *et al.*, 2022). Socioeconomic and behavioral risk factors - including lower education (Singini *et al.*, 2021; Onwuamah *et al.*, 2023) and income levels (Berraho *et al.*, 2017; Abila *et al.*, 2021) - exacerbate CC risk and HPV infection rates. Within-country disparities in education, healthcare access, and economic stability have also been shown to affect HPV vaccine uptake in Mozambique (Haidari *et al.*, 2017).

Reaching underserved populations remains a challenge, particularly for slum residents and nomadic groups in the East African region (Watson-Jones *et al.*, 2015; Bonner, Banura and Basta, 2018; Kutz *et al.*, 2023). School-based delivery systems, while effective, may inadvertently exclude out-of-school adolescents and those in private schools (Lubeya *et al.*, 2024). Furthermore, focusing solely on adolescents overlooks other high-risk groups who could benefit from vaccination (Piñeros *et al.*, 2010). Similar urban-rural disparities in CC incidence further underscore the need for equity-focused vaccination strategies (Berraho *et al.*, 2017; Singini *et al.*, 2021).

Beyond health benefits, HPV vaccination offers financial protection. CC treatment is costly, with screening and treatment in Tanzania averaging US$2,526 (Nelson *et al.*, 2016). This substantial financial burden, which is not covered by the government (Das, 2022), leads to high out-of-pocket expenditures, increasing the risk of financial hardship. High health-related expenses disproportionately impact vulnerable populations, leading to medical impoverishment and widening socioeconomic disparities. A key metric for assessing financial

risk is catastrophic health expenditure (CHE), defined as out-of-pocket spending that exceeds a given income or consumption threshold (Eze *et al.*, 2022).

In addition to reducing CC cases, the HPV vaccination programme could alleviate pressure on the healthcare system (Guillaume *et al.*, 2023). Many African countries face a shortage of healthcare workers, particularly cancer surgeons (Sheffel *et al.*, 2024). Preventing CC cases reduces the demand for cancer treatment, helping mitigate workforce shortages (Brassel *et al.*, 2023). With CC incidence projected to rise in LMICs over the next 50 years - driven by population growth, aging, urbanization, and lifestyle changes (Soerjomataram and Bray, 2021) - ensuring sustainable healthcare workforce capacity is crucial. In Mozambique, healthcare workforce costs constitute 42% of non-communicable disease interventions (Paolo Belardi, Laura Nollino, and Giovanni Putoto, 2024).

The objective of this study was to assess the impact of current HPV vaccination programme efforts, hypothetical scale-up scenarios, and global targets on population health, healthcare workforce, CHE incidence, and health disparities in Mozambique. We evaluated the magnitude and distribution of expected health and economic outcomes across scenarios that assume increased coverage of the HPV vaccine and/or government-funded treatment coverage.

5   Methods

We used the Extended Cost-Effectiveness Analysis (ECEA) framework to evaluate the impact of the current HPV vaccination program, hypothetical scale-up scenarios, and the global coverage target (90%) on population health, the healthcare workforce, CHE incidence, and health disparities (Verguet, Kim and Jamison, 2016).

5.1   The model and its biological assumptions

To estimate health gains, we applied a "closed" cohort model, an epidemiological modeling approach that tracks a defined population over time without accounting for transmission to or from the cohort (Goldie et al., 2008). This model estimates aggregate health outcomes,

which were then stratified by population subgroups. Following the ECEA approach, the model enables the quantification of health benefits across subgroups by accounting for variations in (i) vaccine coverage across different population groups, and (ii) disease burden distribution among these groups. The estimated health gains from the cohort model served as input values to assess benefits from a health system perspective, including the distribution of health improvements and financial risk protection across population subgroups. Figure 1 provides an overview of the model structure and its application within the ECEA framework. Assumptions and data sources are presented in Table 1.

[INSERT FIGURE 1 HERE]

[INSERT TABLE 1 HERE]

5.2 Health gain distribution

Estimated health outcomes were stratified by socioeconomic population subgroup and type of residence (urban or rural). To do this for health outcomes, it was assumed that the distribution of CC incidence across wealth quintiles was the same as that observed in Tanzania (Umuhoza and Ataguba, 2018).

To do this for residence type, it was used data from Mozambique on the distribution of persons in each wealth quintile by urban and rural residence (Instituto Nacional de Estatística, 2021).

5.3 Additional model outcomes

The model was also used to estimate **vaccination programme costs**. We accounted for vaccine wastage, one-time introduction, and recurrent delivery costs (Table 1), following Portnoy, Sweet, *et al.*, 2021. The one-time introduction cost estimate includes non-recurrent introduction activities, i.e., planning, training, social mobilization, and information, education, communication in the first year, while the recurrent cost estimate includes ongoing costs for service delivery.

Health resource requirements were derived from population health outcomes using a needs-based workforce modelling approach (Asamani, Christmals and Reitsma, 2021). With this approach, the number of health professionals, quantified in full-time equivalents (FTE) required to meet a population's health needs was estimated based on the estimated prevalence of the disease and the appropriate standards of care for patients with the disease.

Healthcare need is defined by the number of CC patients by cancer stage per year. Capacity is a function of labour productivity. Labour and productivity estimates from Nelson et al.'s (Nelson *et al.*, 2016) study were used to derive the number of hours required to treat CC patients by cancer stage. In Mozambique, medical staff works 210 days per year, 8 hours a day (Dutta *et al.*, 2014).

Health outcomes by population subgroup are used to estimate **CHE incidence**. For each wealth quintile, CHE incidence was determined by the number of CC cases by stage and wealth quintile, access to CC treatment by wealth quintile, stage-specific direct treatment costs, the proportion of direct medical expenditure financed out of pocket, and annual household expenditure. Supplement 1 provides more information on how parameter values were derived.

5.4   Model scenarios

To evaluate the potential impact of the HPV vaccination program, we modeled several scenarios reflecting different vaccination coverage levels and distribution patterns. The analysis includes a base-case scenario (A) that relies on current vaccination coverage and treatment cost assumptions, scale-up scenarios (C and D) that examine uniform increases in coverage, and coverage distribution scenarios (D and E) that account for variations by wealth quintile and urban versus rural residence. Assumptions for each scenario are provided in Table 2.

[INSERT TABLE 2 HERE]

5.5   Analysis plan

Outcome measures and sensitivity analysis are summarized in Table 3.

[INSERT TABLE 3 HERE]

Population health benefits and resources (labour) saved attributable to the vaccination programme were quantified by estimating the number of CC cases and deaths, as well as vaccination programme costs saved. Further, these outcomes were estimated under the base case scenario (A) and compared to health benefits estimated with the hypothetical scale-up scenarios (B, C). Health benefits estimated in scenario C were compared with health benefits estimated in scenario D.

The difference in CHE incidence between scenarios A and C was quantified and CHE incidence reduction attributable to the vaccination programme was computed. CHE was defined as the number of out-of-pocket spending incidences exceeding 10% of total consumption or income (Eze *et al.*, 2022).

We also compared outcomes of scenarios A and D. We examined how the effect is influenced by alternative assumptions about the access to treatment afforded to people in different income quintiles.

We also explored what proportion of treatment costs would have to be covered by a public finance scheme to reduce CHE incidence, in addition to the vaccination programme.

One-way sensitivity analyses were conducted by varying five key parameters over plausible ranges. Treatment costs and labour requirements in terms of full-time equivalents (FTE) were adjusted by ±20% for each cervical cancer (CC) stage. To assess the impact of different financial risk protection definitions, an alternative CHE threshold was explored by setting it at 40% of non-food household expenditure. Access to treatment was examined under two assumptions: equal access across all wealth quintiles and a gradient increase in access from the poorest to the richest quintile (ranging from 5.9% in the poorest group to 29.6% in the wealthiest, with an average of 22.4%), based on observed trends in Nigeria and

Uganda (Foerster *et al.*, 2019). Finally, CC incidence distribution was tested under two scenarios: one assuming an equal probability of CC across wealth quintiles, and another assuming a lower probability of CC in higher wealth quintiles, modifying the initial distribution based on registry data from Dar es Salaam, Tanzania (Rweyemamu, 2013).

6   Results

6.1   Health impact

Across the lifetime of a single vaccinated cohort, approximately 1,700 cervical cancer cases and 600 cervical cancer deaths, representing 10% of expected cases and deaths, are estimated to be averted. The scale of impact varies by coverage scenario. Under Scenario C, up to 26% of expected cervical cancer cases and deaths would be prevented, while under Scenario B, the reduction would be 46%.

6.2   Health system impact

Total vaccination programme costs were estimated at US$1,080,184, which represents 49% (95% uncertainty interval: 39% – 59%) of the medical treatment costs saved by vaccinating 18.9% of females in the target group. The vaccination programme under Scenario B is associated with costs of US$113M, with cost savings proportionate to vaccination coverage and the medical treatment costs averted.

The estimated labor saved due to vaccination was equivalent to the annual full-time workload of 59 medical personnel under Scenario A. Under Scenario B, an estimated 780,000 hours (624,000 – 936,000) of medical labor would be saved; for one year this corresponds to 7,882 full-time medical personnel. Under Scenario D, the labor saved would amount to 1,664 full-time medical personnel per year.

6.3   Household budget impact

The vaccination programme is expected to significantly reduce CHE related to cervical cancer treatment. With 100% of direct medical costs financed out of pocket, approximately 6,000 cases of CHE and more than US$100M in treatment costs could be averted over the lifetime of 9-year-old females across 30 cohorts. If vaccination coverage is higher among wealthier population sub-groups, the number of CHE cases averted would be reduced by 200 persons.

If CHE is measured using a threshold of 40% of non-food annual household expenditure, the incidence would be similar to estimates using a 10% threshold of total annual household

expenditure. If the CHE threshold is defined as 10% of annual household expenditure and a public financing scheme in Mozambique were to cover 76% of direct medical treatment costs, the incidence of CHE would be reduced by 10%. Ninety-six percent of direct medical treatment costs would need to be covered to avert 51% of CHE incidence. If CHE is defined using a threshold of 40% of non-food annual household expenditure, public financing covering 26% of direct medical treatment costs would reduce CHE incidence by 11%, whereas 92% coverage of direct medical costs would be required to avert 51% of CHE cases.

[INSERT FIGURE 2 HERE]

6.4 Distributional impact

The distribution of benefits from the vaccination programme varies across population sub-groups. Under Scenario D, the primary beneficiaries are individuals in the two lowest-income quintiles, with the poorest quintile receiving 26% of the total benefits, followed closely by the second-poorest quintile at 23%. Overall, 68% of benefits accrue to the lowest, lower-middle, and middle-income quintiles, representing the bottom 60% of the population. If the risk of cervical cancer were equal across all wealth quintiles, the highest number of cases averted would occur in the wealthiest group due to higher vaccination coverage.

[INSERT FIGURE 3 HERE]

Under Scenario C, 30% of expected benefits would be concentrated in the lowest income quintile, and the highest number of CHE cases would be averted in this group. Estimated health gains under Scenario E would primarily benefit the highest-income urban population due to greater access to treatment, where 7% of expected cervical cancer cases would be prevented. In rural areas, the largest health benefits would accrue to the second-lowest income quintile, with an estimated 3% of expected cervical cancer cases averted.

[INSERT FIGURE 4 HERE]

As expected, if individuals in the poorest socio-economic quintile have limited access to treatment, the highest number of CHE cases averted would be among the highest-income groups under both Scenarios C and D, regardless of the CHE threshold definition applied.

7   Discussion

This study applied an established model of HPV, cervical cancer (CC), and the Extended Cost-Effectiveness Analysis (ECEA) framework to evaluate the impact of Mozambique's recently introduced HPV vaccination program from both a patient and health system perspective. The findings highlight that while the vaccination program has the potential to substantially improve population health outcomes and provide financial risk protection, its benefits are not distributed equally across socioeconomic groups.

The concentration of benefits among wealthier populations is primarily driven by the correlation between lower income, greater baseline risk of CC, and limited access to care. Even when vaccine distribution is equal, disparities in disease burden and healthcare access mean that wealthier populations experience greater relative gains. Ensuring equitable benefits would require targeted efforts to improve uptake in rural and lower-income populations.

The analysis also suggests that reducing out-of-pocket payments for CC treatment could mitigate CHE, but significant financial protection would only be achieved if treatment costs were predominantly subsidized by the state – particularly for individuals in the lowest socioeconomic quintile. In this scenario, fully state-funded treatment would be necessary to reduce CHE incidence by half.

Overall, these findings underscore the importance of both high vaccination coverage and financial protection measures to maximize the program's equity impact. Expanding vaccine outreach to underserved populations and increasing financial support for CC treatment could enhance both health and economic benefits across all population groups.

Several limitations of this study need to be acknowledged. These relate to simplifying assumptions made around input parameters as well as the model structure. Firstly, national epidemiological information on age-specific CC incidence was available, but incidence rates were only based on the registry of two hospitals located in Beira in central Mozambique and Maputo in the south of Mozambique. The lack of data from other parts of the country and poor quality data on CC is likely to result in an underestimated number of CC cases, as observed in neighbouring Eswatini (Ginindza and Sartorius, 2018). Thus, the estimated impact of the vaccination programme is likely to be higher.

Secondly, data from a cohort study conducted in Dar es Salaam, Tanzania, informed the assumption that CC incidence is higher in the poorest quintiles. However, the reliability of this data is uncertain, as it was collected from a single hospital in Tanzania and has not been published in peer-reviewed literature. To account for potential variations, we explored different distributions of CC incidence across wealth quintiles. Our analysis showed that when CC risk is assumed to be uniform across all income groups and vaccination coverage follows a gradient favoring wealthier quintiles, the greatest health benefits accrue to the highest income group. This is because higher coverage in wealthier populations results in a larger absolute reduction in CC cases, even when baseline risk is the same across groups. However, this scenario - where the highest income quintile benefits the most - only occurs when coverage is skewed toward wealthier groups while all other factors remain constant. In reality, CC incidence is more likely to decrease with increasing income, a pattern observed in multiple countries (Chang *et al.*, 2018). This suggests that, without targeted efforts to increase vaccination rates among lower-income groups, disparities in CC burden may persist or even widen.

Similarly, the assumption that access to treatment is higher in wealthier quintiles was informed by the distribution of access to general care. This information is a poor proxy for access to vaccination for adolescents as the information is for the entire household and concerns the use of general care. Thus, given the possibility that this distribution is different

for access to CC treatment access, a gradient increase in access to treatment by wealth quintile was explored in the sensitivity analysis. Unsurprisingly, increased access to care significantly shifts the distribution of financial protection provided to the highest-income group. However, the fact that the highest quintile experiences CHE under both definitions underscores just how high the cost of treatment is relative to income, even in the wealthiest segments of the population.

Thirdly, the vaccination coverage data used in the status quo scenario, while based on reported figures, are subject to considerable uncertainty. Interviews revealed inaccuracies in the 2011 census data, the denominator for coverage calculations. Given that these coverage estimates were likely not adjusted prior to being shared, the actual coverage achieved in the program's first year is likely lower than reported. While a more recent Post Enumeration Survey (PES) indicated a 3.7% undercount in the census, this does not fully address the potential inaccuracies in the older data used for the initial coverage calculations. Furthermore, coverage of the final dose reached 42.1% in 2021 (Kouassi *et al.*, 2024), suggesting potential higher coverage rates in the future.

Therefore, to explore the sensitivity of our findings to coverage levels, we also analyzed scenarios with 50% and 90% coverage. The results across this range of coverage rates consistently demonstrate the value of investing in scaling up the program. This suggests that even with the inherent uncertainty surrounding the precise coverage achieved, the program's impact and benefits to the healthcare system are substantial. While our model demonstrates the cost-effectiveness of the intervention across a range of scenarios, it is important to acknowledge that real-world implementation may involve scale-dependent cost variations. Our estimates assume vaccine distribution through fixed facilities, which may underestimate the additional costs required to reach remote or underserved populations. Outreach programs, for example, introduce extra logistical expenses, increasing the cost per fully immunized girl compared to fixed-facility delivery. Additionally, vaccination costs can vary depending on the chosen delivery strategy and the scale of implementation. Economies of

scale could reduce per-dose costs in large-scale rollouts, whereas logistical challenges at higher coverage levels may drive costs up. Direct non-medical expenses, such as transportation, may also vary by wealth quintile and place of residence, influencing financial burden and access to care. Thus, the cost estimates presented in this study are conservative, as they do not fully account for these scale-dependent variations. Despite this, the consistent positive impact of increased coverage across plausible cost scenarios strengthens the case for expanding the vaccination program.

Fourthly, we adopted treatment cost and labor requirement estimates from Tanzania, which has a similar Healthcare Access and Quality Index (Fullman *et al.*, 2018) and was therefore presumed to have comparable treatment capacities. This approach was necessary due to the lack of treatment cost data specific to Mozambique. However, the available data did not include uncertainty ranges, so all cost estimates were adjusted with a ±20% interval to reflect the high degree of uncertainty in this input value.

The distribution of access to treatment across wealth quintiles is likely to be a fair representation of the access to different types of healthcare in Mozambique as they are informed by a large Household Budget Survey conducted by the National Institute of Statistics of Mozambique with a sample size of 11,480 households (58,118 individuals). The authors of the technical report in which this estimate is published have noted there is high within-country variability in access to private healthcare, mostly concentrated in the southern region. Due to this provincial level heterogeneity and potential changes since the date of the survey (2014/15) Access to treatment assumptions were varied in sensitivity analysis.

Moreover, empirical studies on the distribution of detected cancers by cancer stage in Mozambique have not been published in the literature. Thus, the validity of the estimated distribution cannot be ascertained.

This model does not include the effects of HPV vaccination in reducing onward transmission. As such, the health impact of vaccination was under-estimated. Indeed there is strong

evidence for vaccine cross-protection and herd effects from the HPV vaccine if coverage is 50% or above (Drolet *et al.*, 2019). Similarly, we relied on research conducted in Mozambique to inform the HPV 16, 18 type distribution to which the model is very sensitive (Portnoy, Abbas, *et al.*, 2021). . We also did not include the potential health benefits and costs associated with other preventive interventions, such as screening or treatment for precancerous lesions. Evaluations of combined strategies conducted in other countries concluded that, together, the interventions have the potential to eliminate CC (Brisson *et al.*, 2020). Indirect costs, i.e., wages lost due to the inability of the patient or accompanying family members to work, were not estimated. These additional cost savings would further decrease CHE incidence. Further, household consumption only accounts for goods and services, i.e., the net of expenditure. Thus, CHE incidence estimates are possibly underestimated.

Due to limited data on medical resource requirements for CC patients and overall healthcare demand in Mozambique, we estimated only the labor saved as an example of the vaccine's value to the health sector. In theory, reducing CC-related healthcare demands could allow resources to be redirected to other treatment services. However, in practice, healthcare resources are often over-committed, meaning that spare capacity may not necessarily become available. Patients who survive due to vaccination will continue to engage with healthcare services for other needs, which could offset some of the estimated resource savings. Future research could explore these dynamics further, including estimating additional resources saved, such as hospital bed days.

The ECEA framework used in this study to assess the distributional consequences of Mozambique's HPV vaccination programme has previously been applied to evaluate the equity impact of other vaccines, including the HPV vaccine in other countries. This study adds to the existing literature by providing evidence on the health and economic impact of HPV vaccination specifically in Mozambique. The findings align with prior research, confirming that HPV infection disproportionately affects marginalized and lower-income

populations due to limited access to screening and early detection (Driessen *et al.*, 2015; Levin *et al.*, 2015; Loganathan *et al.*, 2016; Portnoy, Sweet, *et al.*, 2021). Consequently, the greatest health benefits of the vaccination programme are concentrated in the lowest wealth quintiles. However, the financial benefits, in absolute terms, accrue more to wealthier households, given their greater ability to afford care and avoid catastrophic health expenditures. In relative terms, the financial relief may still be significant for lower-income households, given their higher risk of financial hardship from out-of-pocket medical expenses. While this analysis provides valuable insights into the distributional consequences of HPV vaccination, it does not quantify the programme's impact on overall inequality in lifetime health. A distributional cost-effectiveness analysis (Dawkins *et al.*, 2018) could complement this research by further exploring broader dimensions of the vaccine's value and its impact on health disparities.

A key aspect of this modeling effort was collaboration with in-country partners to assess the availability and quality of local data. While data limitations posed significant challenges, the process itself provided valuable insights into why specific data are necessary for robust health policy modeling. In this way, this work highlighted critical data gaps and informing future data collection efforts. Additionally, engagement with Mozambican stakeholders played a role in shaping the research outcomes, including necessary model adaptations. This underscores the value of participatory modeling approaches in ensuring that analyses remain relevant and actionable within local contexts.

8   Conclusion

This study presents a comprehensive assessment of the HPV vaccination programme in Mozambique, considering its impact from a population health, health system, and patient perspective. The analysis of distributional effects across residence types and income groups is particularly relevant to Mozambique's National Cancer Control Plan, which is currently under development (World Health Organization, 2022). The findings contribute to ongoing

policy dialogues by providing evidence to support fair and efficient decision-making in HPV

vaccination planning at both national and global levels.

9 References

Abbas, K. *et al.* (2024) 'Equity impact of HPV vaccination on lifetime projections of cervical cancer burden among cohorts in 84 countries by global, regional, and income levels, 2010–22: a modelling study', *eClinicalMedicine*, 70, p. 102524. Available at: https://doi.org/10.1016/j.eclinm.2024.102524.

Abila, D.B. *et al.* (2021) 'Burden of Risk Factors for Cervical Cancer Among Women Living in East Africa: An Analysis of the Latest Demographic Health Surveys Conducted Between 2014 and 2017', *JCO Global Oncology*, (7), pp. 1116–1128. Available at: https://doi.org/10.1200/GO.21.00123.

Ali, H.A. *et al.* (2022) 'Vaccine equity in low and middle income countries: a systematic review and meta-analysis', *International Journal for Equity in Health*, 21(1), p. 82. Available at: https://doi.org/10.1186/s12939-022-01678-5.

Anonymous Interviewee (2023) 'Interview conducted for the study: A participatory approach to developing and using evidence from mathematical models – A case study of the HPV vaccine introduction in Mozambique'.

Asamani, J., Christmals, C. and Reitsma, G. (2021) 'Advancing the Population Needs-Based Health Workforce Planning Methodology: A Simulation Tool for Country Application', *International Journal of Environmental Research and Public Health*, 18(4), p. 2113. Available at: https://doi.org/10.3390/ijerph18042113.

Berraho, M. *et al.* (2017) 'HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study', *BMC Cancer*, 17(1), p. 435. Available at: https://doi.org/10.1186/s12885-017-3425-z.

Bonner, K., Banura, C. and Basta, N.E. (2018) 'HPV vaccination strategies targeting hard-to-reach populations: Out-of-school girls in LMICs', *Vaccine*, 36(2), pp. 191–193. Available at: https://doi.org/10.1016/j.vaccine.2017.11.038.

Brandão, M. *et al.* (2019) 'Cervical cancer screening uptake in women aged between 15 and 64 years in Mozambique', *European Journal of Cancer Prevention*, 28(4), pp. 338–343. Available at: https://doi.org/10.1097/CEJ.0000000000000459.

Brassel, S. *et al.* (2023) 'The Value of Vaccines in Maintaining Health System Capacity in England', *Value in Health*, 26(7), pp. 1067–1072. Available at: https://doi.org/10.1016/j.jval.2022.06.018.

Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. Available at: https://doi.org/10.3322/caac.21492.

Brisson, M. *et al.* (2020) 'Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries', *The Lancet*, 395(10224), pp. 575–590. Available at: https://doi.org/10.1016/S0140-6736(20)30068-4.

Canfell, K. *et al.* (2020) 'Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries', *The Lancet*, 395(10224), pp. 591–603. Available at: https://doi.org/10.1016/S0140-6736(20)30157-4.

Chang, A.Y. *et al.* (2018) 'The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries', *Health Affairs*, 37(2), pp. 316–324. Available at: https://doi.org/10.1377/hlthaff.2017.0861.

Das, M. (2022) 'Mozambique takes on cancer burden challenges', *The Lancet Oncology*, 23(3), p. 334. Available at: https://doi.org/10.1016/S1470-2045(22)00080-8.

Dawkins, B.R. *et al.* (2018) 'Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia', *Health Policy and Planning*, 33(3), pp. 456–463. Available at: https://doi.org/10.1093/heapol/czx175.

De Martel, C. *et al.* (2017) 'Worldwide burden of cancer attributable to HPV by site, country and HPV type', *International Journal of Cancer*, 141(4), pp. 664–670. Available at: https://doi.org/10.1002/ijc.30716.

Driessen, J. *et al.* (2015) 'Comparing the health and social protection effects of measles vaccination strategies in Ethiopia: An extended cost-effectiveness analysis', *Social Science & Medicine*, 139, pp. 115–122. Available at: https://doi.org/10.1016/j.socscimed.2015.06.018.

Drolet, M. *et al.* (2019) 'Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis', *The Lancet*, 394(10197), pp. 497–509. Available at: https://doi.org/10.1016/S0140-6736(19)30298-3.

Dutta, A. *et al.* (2014) *Estimated Resource Needs and Impact of Mozambique's Plano Estrategico Do Sector Saude, 2014–2019*. Washington, DC: Futures Group, Health Policy Project.

Eze, P. *et al.* (2022) 'Catastrophic health expenditure in sub-Saharan Africa: systematic review and meta-analysis', *Bulletin of the World Health Organization*, 100(05), pp. 337-351J. Available at: https://doi.org/10.2471/BLT.21.287673.

Foerster, M. *et al.* (2019) 'Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study', *Breast Cancer Research*, 21(1), p. 93. Available at: https://doi.org/10.1186/s13058-019-1174-4.

Fullman, N. *et al.* (2018) 'Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016', *The Lancet*, 391(10136), pp. 2236–2271. Available at: https://doi.org/10.1016/S0140-6736(18)30994-2.

Garland, S.M. *et al.* (2007) 'Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases', *New England Journal of Medicine*, 356(19), pp. 1928–1943. Available at: https://doi.org/10.1056/NEJMoa061760.

Ginindza, T.G. and Sartorius, B. (2018) 'Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates', *BMC Cancer*, 18(1), p. 639. Available at: https://doi.org/10.1186/s12885-018-4540-1.

Gironés, A.L. *et al.* (2020) *Health care inequalities in Mozambique: needs, access, barriers and quality of care.* Available at: https://www.medicusmundimozambique.org/files/2020/07/inequalities-technicalreport-eng-2.pdf.

Guillaume, D. *et al.* (2023) 'Factors influencing the prioritization of vaccines by policymakers in low- and middle-income countries: a scoping review', *Health Policy and Planning*, 38(3), pp. 363–376. Available at: https://doi.org/10.1093/heapol/czac092.

Haidari, L.A. *et al.* (2017) 'Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique', *Sexually Transmitted Diseases*, 44(4), pp. 222–226. Available at: https://doi.org/10.1097/OLQ.0000000000000574.

Hildesheim, A. *et al.* (2014) 'Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial', *Vaccine*, 32(39), pp. 5087–5097. Available at: https://doi.org/10.1016/j.vaccine.2014.06.038.

Instituto Nacional de Estatística (2021) *Inquérito sobre orcamento familiar - IOF 2019/20*.

International agency for research on cancer (2020) 'International agency for research on cancer: GLOBOCAN 2020. Cancer incidence, mortality and prevalence worldwide.'

International agency for research on cancer - The Global Cancer Observatory (2022) *Mozambique Factsheet*. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/508-mozambique-fact-sheet.pdf.

Kouassi, K.S. *et al.* (2024) 'Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030', *Vaccine*, 42, pp. S33–S36. Available at: https://doi.org/10.1016/j.vaccine.2023.08.057.

Kutz, J.-M. *et al.* (2023) 'Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review', *BMC Public Health*, 23(1), p. 974. Available at: https://doi.org/10.1186/s12889-023-15842-1.

Levin, C.E. *et al.* (2015) 'An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China', *Vaccine*, 33(24), pp. 2830–2841. Available at: https://doi.org/10.1016/j.vaccine.2015.02.052.

Loganathan, T. *et al.* (2016) 'Rotavirus vaccines contribute towards universal health coverage in a mixed public–private healthcare system', *Tropical Medicine & International Health*, 21(11), pp. 1458–1467. Available at: https://doi.org/10.1111/tmi.12766.

Lorenzoni, C. *et al.* (2018) 'Weak surveillance and policy attention to cancer in global health: the example of Mozambique', *BMJ Global Health*, 3(2), p. e000654. Available at: https://doi.org/10.1136/bmjgh-2017-000654.

Lubeya, M.K. *et al.* (2024) 'Selecting and Tailoring Implementation Strategies to Improve Human Papillomavirus Vaccine Uptake in Zambia: A Nominal Group Technique Approach', *Vaccines*, 12(5), p. 542. Available at: https://doi.org/10.3390/vaccines12050542.

Nelson, S. *et al.* (2016) 'Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries', *Value in Health Regional Issues*, 10, pp. 1–6. Available at: https://doi.org/10.1016/j.vhri.2016.03.002.

Omotoso, O. *et al.* (2023) 'Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions', *International Journal for Equity in Health*, 22(1), p. 189. Available at: https://doi.org/10.1186/s12939-023-01962-y.

Onwuamah, C.K. *et al.* (2023) 'Prevalence and risk factors for high-risk human papillomavirus infection among women from three southern geopolitical zones of Nigeria', *Frontiers in Oncology*, 13, p. 1254304. Available at: https://doi.org/10.3389/fonc.2023.1254304.

Paolo Belardi, Laura Nollino, and Giovanni Putoto (2024) *Research on the costs of NCDs in Mozambique*. 89. Doctors with Africa CUAMM. Available at: https://doctorswithafrica.org/en/wp-content/uploads/sites/2/2025/01/HeD_89_nov24-belardi.pdf.

Piñeros, M. *et al.* (2010) 'HPV vaccine introduction at the local level in a developing country: attitudes and criteria among key actors', *Cadernos de Saúde Pública*, 26(5), pp. 900–908. Available at: https://doi.org/10.1590/S0102-311X2010000500012.

Portnoy, A., Sweet, S., *et al.* (2021) 'Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study', *Health Policy and Planning*, 36(6), pp. 891–899. Available at: https://doi.org/10.1093/heapol/czab052.

Portnoy, A., Abbas, K., *et al.* (2021) 'Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study', *BMJ Global Health*, 6(11), p. e006940. Available at: https://doi.org/10.1136/bmjgh-2021-006940.

'Prevention, diagnosis and management of cancer in Mozambique' (2021). Available at: https://www.iccp-portal.org/system/files/resources/ICCP%202021%20%20Baker.pdf.

Rweyemamu, K.Y. (2013) *Factors associated with cervical cancer among women attending referral hospitals in Dar es Salaam, Tanzania*.

Sacre, A. *et al.* (2023) 'Socioeconomic inequalities in vaccine uptake: A global umbrella review', *PLOS ONE*. Edited by L. Brunelli, 18(12), p. e0294688. Available at: https://doi.org/10.1371/journal.pone.0294688.

Sheffel, A. *et al.* (2024) 'Human resource challenges in health systems: evidence from 10 African countries', *Health Policy and Planning*, 39(7), pp. 693–709. Available at: https://doi.org/10.1093/heapol/czae034.

Singini, M.G. *et al.* (2021) 'Ranking lifestyle risk factors for cervical cancer among Black women: A case-control study from Johannesburg, South Africa', *PLOS ONE*. Edited by N. Erbil, 16(12), p. e0260319. Available at: https://doi.org/10.1371/journal.pone.0260319.

Soerjomataram, I. and Bray, F. (2021) 'Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070', *Nature Reviews Clinical Oncology*, 18(10), pp. 663–672. Available at: https://doi.org/10.1038/s41571-021-00514-z.

Sung, H. *et al.* (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. Available at: https://doi.org/10.3322/caac.21660.

Tsu, V.D. and Levin, C.E. (2008) 'Making the case for cervical cancer prevention: what about equity?', *Reproductive Health Matters*, 16(32), pp. 104–112. Available at: https://doi.org/10.1016/S0968-8080(08)32411-2.

Tulsidás, S. *et al.* (2023) 'Oncology in Mozambique: Overview of the Diagnostic, Treatment, and Research Capacity', *Cancers*, 15(4), p. 1163. Available at: https://doi.org/10.3390/cancers15041163.

Umuhoza, S.M. and Ataguba, J.E. (2018) 'Inequalities in health and health risk factors in the Southern African Development Community: evidence from World Health Surveys', *International Journal for Equity in Health*, 17(1), p. 52. Available at: https://doi.org/10.1186/s12939-018-0762-8.

Verguet, S., Kim, J.J. and Jamison, D.T. (2016) 'Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial', *PharmacoEconomics*, 34(9), pp. 913–923. Available at: https://doi.org/10.1007/s40273-016-0414-z.

Watson-Jones, D. *et al.* (2015) 'Access and Attitudes to HPV Vaccination amongst Hard-To-Reach Populations in Kenya', *PLOS ONE*. Edited by M.E.L. Consolaro, 10(6), p. e0123701. Available at: https://doi.org/10.1371/journal.pone.0123701.

World Health Organization (2022) *Mozambique: strengthening efforts to reduce the cancer burden*. Available at: https://www.who.int/news-room/feature-stories/detail/mozambique-strengthening-efforts-to-reduce-the-cancer-burden.

10 Figure and Table Legends

Table 1 Parameter values (at baseline).

Table 2 Analytical scenarios modelled.

Table 3 Outcome measures by analytic scenario.

Figure 1 Schematic of the extended cost effectiveness analysis (ECEA) approach application. Population health gains (grey box) are estimated using Goldie et al.'s static cohort model. All other outcomes are computed with outcomes from Goldie et al.'s model.

Figure 2 Catastrophic health expenditure (CHE) incidence with increasing medical treatment coverage for cervical cancer patients by socio-economic quintile with a threshold of (A) 10% of annual household consumption, and (B) 40% of annual non-food household consumption.

Figure 3 Predicted number of averted cases by socio-economic quintile under different cervical cancer (CC) risk distribution across wealth quintiles by vaccination coverage scenario. (i) 50% coverage of the HPV vaccine across wealth quintiles, and (ii) 50% of coverage of the HPV vaccine across wealth quintiles, and (ii) 50% of coverage at an increasing gradient from lowest to highest socio-economic quintile.

Figure 4 Estimated averted cervical cancer (CC) cases in percentage by wealth quintile and type of residence assuming a vaccination coverage gradient across population sub-groups living in different types of residence.

Supplement 1 provides additional methodological details supporting the analysis presented in the manuscript, specifically on estimating household expenditures, cancer stage distribution, and access to cervical cancer (CC) treatment in Mozambique.

Health and economic impact of the human papillomavirus (HPV) vaccine in Mozambique

Table 1 Parameter values (at baseline).

Parameter	Value	Reference
Female population in Mozambique	Total female population as of 2022: 16,793,302	(United Nations Department of Economic and Social Affairs Population Division, 2022)
CC incidence by age		(Union for International Cancer Control, 2019)
HPV-16/18 type distribution	0.51/0.49	(Edna Omar *et al.*, 2017)
Stage distribution of detected cancers by FIGO stage	Stage I: 0.09 Stage II: 0.36 Stage III: 0.47 Stage IV: 0.08	(Carrasco-Escobar, Fornace and Benmarhnia, 2021)
Vaccination coverage	18.9%	Empirical
Vaccine wastage	5%	(Parmar *et al.*, 2010)
One-time-introduction cost per targeted girl in US$	2.00	(Portnoy *et al.*, 2021)
Recurrent delivery cost per girl in US$	1.70	(Portnoy *et al.*, 2021)
Vaccine price per dose in US$	4.50	(Portnoy *et al.*, 2021)
Distribution of CC incidence across wealth quintiles	Q1: 29.7% Q2: 20.9% Q3: 24.7% Q4: 13.9% Q5: 10.8%	(Rweyemamu, 2013)
Distribution of wealth quintiles across residence types	Urban Q1: 57% Urban Q2: 27% Urban Q3: 9% Urban Q4: 3% Urban Q5: 4% Rural Q1: 27% Rural Q2: 28% Rural Q3: 25% Rural Q4: 17% Rural Q5: 3%	(Instituto Nacional de Estatística, 2021)
Distribution of population across types of residence	Urban: 38% Rural: 62%	(Instituto Nacional de Saúde and ICF/Programa DHS, 2015)
Direct medical treatment costs by FIGO stage in US$	Stage I: 2,989 Stage II: 2,999 Stage III: 1,744 Stage IV: 1,741	(Nelson *et al.*, 2016)
Proportion of direct medical treatment costs covered by healthcare provider	0	(Das, 2022)
CHE threshold	10% of annual household expenditure	(Eze *et al.*, 2022)
Average household size	4.78	(Instituto Nacional de

		Estatística, 2021)
Monthly per capita consumption in MZN (2019/20)	Q1: 224 Q2: 585 Q3: 990 Q4: 1,655 Q5: 5,022	(Instituto Nacional de Estatística, 2021)
Proportion of patients seeking treatment at Central Private Hospital	4.70%	(Gironés *et al.*, 2020)
Access to general care by wealth quintile	Q1: 57.0% Q2: 67.8% Q3: 66.6% Q4: 79.9% Q5: 81.8%	(Instituto Nacional de Estatística, 2021)
Medical personnel labour cost by FIGO stage in US$	Stage I: 106.95 Stage II: 117.39 Stage III: 105.16 Stage IV: 102.24	(Nelson *et al.*, 2016)
Annual treatment capacity for CC patients at public hospital	900	('Prevention, diagnosis and management of cancer in Mozambique', 2021)
Demand for CC treatment (2021)	5,325	(Bray *et al.*, 2018)

Health and economic impact of the human papillomavirus (HPV) vaccine in Mozambique

Table 1 Analytical scenarios modelled.

Scenario label	Scenario	Description	Coverage	Source for assumption
A	Base case	Informed by vaccination coverage, assumed to be uniformly distributed across the population, recorded in the first year of the programme (2021).	18.9%	Anonymous Interviewee, 2023
B	Global target	Informed by global Cervical Cancer Elimination Initiative target.	90%	Cervical Cancer Elimination Initiative's goal
C	Half-way, flat coverage	Vaccination coverage is uniformly dis- tributed across wealth quintiles.	50%	
D	Half-way, gradient coverage by quintile	The vaccination programme is assumed to have a gradient coverage across wealth quintiles, with an overall weighted vaccine coverage average of 50% across the population. The gradient is empirically informed by access to general healthcare.	Q1: 41.2% Q2: 40.6% Q3: 44.7% Q4: 55.3% Q5: 68.2%	Instituto Nacional de Estatística, 2021
E	Half-way, gradient coverage by residence	The vaccination programme is assumed to have a gradient coverage across populations living in different areas of residence (Instituto Nacional de Saúde and ICF/Programa DHS, 2015), with an overall weighted vaccine coverage average of 50% across the population. The gradient is empirically informed by access to general healthcare.	Urban: 63.9% Rural: 36.1%	Instituto Nacional de Estatística, 2021

Health and economic impact of the human papillomavirus (HPV) vaccine in Mozambique

Table 1 Outcome measures by analytic scenario.

Vaccination programme impact measure	Vaccination scenarios analysed	Parameter varied in sensitivity analyses
Population health benefits in CC cases and deaths, resources saved in financial and labour, and vaccination programme costs	- Base case (A) - Global target (B) - Half-way, flat coverage (C)	- Treatment costs: ±20% - Labour required by FIGO stage: ±20%
Financial risk protection provided in CHE incidence	- Half-way, flat coverage (C) - Half-way, gradient coverage by quintile (D)	CHE threshold: 40% of annual non-food household expenditure
Distribution of benefits across population subgroups	- Half-way, flat coverage (C) - Half-way, gradient coverage by quintile (D) - Half-way, gradient coverage by residence (E)	Access to treatment by wealth quintile: - Equal access to treatment at 22.4% - Gradient increase from Q1: 5.9% to Q5: 29.6% - Risk of developing CC: Equal risk of CC across wealth quintiles - Gradient decrease in risk of CC by wealth quintile